Caribou Biosciences
NASDAQ: CRBUBerkeley, US · Founded 2011 · Delaware corporation · 128 employees on LinkedIn · 9 known investors
Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform. The company licenses foundational CRISPR-Cas9 intellectual property and advances drug candidates for patients with devastating diseases.
Founders & leadership
Caribou Biosciences was founded in 2011 by Jennifer Doudna, Rachel Haurwitz, Martin Jinek, and Andrew May.
JD
Jennifer DoudnaCo-founder
RH
Rachel HaurwitzPresident and Chief Executive Officer, Co-founder30 Under 30 2022
MJ
Martin JinekCo-founder
AM
Andrew MayCo-founder
Board
JR
Jenny RookeBoard director
RW
RB
Rodolphe BarrangouBoard director
Investors · 9
Aliment CapitalLos Angeles · $3M – $5M
Avego BioScience CapitalAlpharetta
F-Prime CapitalCambridge · $3M – $10Mvia Robert Weisskoff · board
IA Seed VenturesBerkeley
Mission Bay CapitalSan Francisco
Mission BiocapitalSan Francisco · $500K
Pontifax AgTechSanta Monica
Anterra CapitalreportedAmsterdam · $20M
Maverick VenturesreportedSan Francisco · $3M – $10M
Reported raises · per SEC filings
Form D private placements$141M disclosed across 3 rounds · 2014–2021
▶$115MraisedMar 2021 · 36 investors · BiotechnologyRule 506(b)
▶$115MraisedMar 2021 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert WeisskoffDirector
- Steven B. KannerExecutive Officer
- Natalie R. SacksDirector
- Santhosh PalaniDirector
- Jeffrey Long-McGieDirector
- Rachel E. HaurwitzExecutive Officer, Director
- Jason O'ByrneExecutive Officer
- Barbara G. McClungExecutive Officer
- Offering amount
- $115M
- Amount sold
- $115M
- Sales commissions
- $5.6M
- Placement agents
- SVB Leerink LLC
- First sale
- Mar 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14.5MraisedMay 2016 · 11 investors · BiotechnologyRule 506(b)
▶$14.5MraisedMay 2016 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jenny RookeDirector
- Rodolphe BarrangouDirector
- Robert WeisskoffDirector
- Andrew P. MayExecutive Officer
- Rachel E. HaurwitzExecutive Officer, Director
- Barbara G. McClungExecutive Officer
- Un Kwon-CasadoExecutive Officer
- Philip AustinDirector
- Offering amount
- $30.1M
- Amount sold
- $14.5M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$11.5MraisedMar 2015 · 14 investors · BiotechnologyRule 506(b)
▶$11.5MraisedMar 2015 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew MayExecutive Officer
- Rodolphe BarrangouDirector
- Rachel HaurwitzExecutive Officer, Director
- Jenny RookeDirector
- Robert WeisskoffDirector
- Offering amount
- $11.5M
- Amount sold
- $11.5M
- First sale
- Sep 2014
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Caribou Biosciences went on to found or lead other companies.
Competitors · 3
by search overlap
Robinhood32 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Bridgebio28 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
AskBio26 shared keywordsAskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.
Companies competing with Caribou Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Caribou Biosciences do?
- Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform. The company licenses foundational CRISPR-Cas9 intellectual property and advances drug candidates for patients with devastating diseases.
- Who founded Caribou Biosciences?
- Caribou Biosciences was founded by Jennifer Doudna, Rachel Haurwitz, Martin Jinek, Andrew May in 2011.
- Who are Caribou Biosciences's investors?
- Caribou Biosciences's investors include Aliment Capital, Avego BioScience Capital, F-Prime Capital, IA Seed Ventures, Mission Bay Capital, Mission Biocapital, Pontifax AgTech, Anterra Capital and 1 more.
- How much funding has Caribou Biosciences raised?
- Caribou Biosciences has disclosed $141M raised across 3 rounds.
- Where is Caribou Biosciences headquartered?
- Caribou Biosciences is headquartered in Berkeley, US.